CLOs on the Move

HASTINGS and PRINCE ED CNTY HLTH

www.hpechu.on.ca

 
HASTINGS & PRINCE ED CNTY HLTH is a Belleville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

The Burke Rehabilitation Hospital

The Burke Rehabilitation Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. The Burke Rehabilitation Hospital is based in White Plains, NY. You can find more information on The Burke Rehabilitation Hospital at www.burke.org

GCG Communications

GCG Communications is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capitol Drugs

Capitol Drugs is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Sherman Oaks, CA. To find more information about Capitol Drugs, please visit www.capitoldrugs.com

Diligent Robotics

We are a human-centered robotics company. Our mission is to make technical advances towards robots and humans working together side by side, with an emphasis on human-centric design. Diligent Robotics is developing a suite of artificial intelligence that enables robots to collaborate with and adapt to humans in everyday environments.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.